PNC-27 / Studies

Conjugate · 32 amino acids · 4,032 Da

PNC-27 studies and research data

PepBank has 20 PNC-27 studies with results. 12 of them gave PNC-27, with 41 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 41 results and 24 papers. Newer studies from Europe PMC

Results in people

0% of 41 results

Results in animals

12% of 41 results

Results in lab cells

88% of 41 results

From computer models

0% of 41 results

The molecule

PNC-27 identity

Identifiers, parent molecule, targets and development stage, from curated data.

PNC-27 is a 32-residue research conjugate. Its first 15 residues correspond to human p53 positions 12 to 26. A 17-residue membrane-penetrating sequence follows. Indexed publication titles identify membrane-associated MDM2, also called HDM-2, as a proposed binding target. PNC-28 is a distinct construct. The community source states that no human clinical trials exist. The record uses the existing immune_antimicrobial area, as the coordinator decided.

Kind: Conjugate · 32 residues
Identifiers: UniProtP04637 (opens in a new tab)PubChem CID16201774 (opens in a new tab)
Parent: Fragment of Cellular tumor antigen p53 · residues 12-26The first 15 residues match p53 12-26. The remaining 17 residues form the membrane-penetrating segment.
Development: PreclinicalThe community source states that no human clinical trials have been conducted. ClinicalTrials.gov returned zero PNC-27 or PNC27 matches. This name search cannot exclude unregistered trials or other names. Preclinical status follows the source description. Cancer claims and case reports do not establish a clinical development phase. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
MDM2 (HDM-2)MDM2Q00987 (opens in a new tab)	Proposed membrane binding	curated database or regulator descriptionSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

32 amino acids · 1 modification

H-

PPLSQETFSD

LWKLLKWKM

RRNQFWVKVQ

-OH

Parent: Cellular tumor antigen p53

No sequence is listed for the parent, so no alignment is shown.The first 15 residues match p53 12-26. The remaining 17 residues form the membrane-penetrating segment.

Properties

From identity sources

Formula: C₁₈₈H₂₉₃N₅₃O₄₄S
Molecular weight: 4,032 g/mol
Monoisotopic mass: 4,029.204 Da

PubChem CID 16201774(opens in a new tab)retrieved 2026-10-21

Calculated from the sequence

pKa set

Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): −0.984; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 16,500 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index: 49.71; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; Above 40: classed as possibly unstable (ExPASy).
Aliphatic index: 66.9; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 2.40 kcal/mol; Mean solubility value (negated) · Boman 2003; 2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH): 0.713; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984

Not included: other modification. Mass, charge and pI are not calculated; use the identity-source values.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Composition

Hydrophobic22% (7)L M V
Aromatic16% (5)F W
Positive25% (8)K R
Negative6% (2)D E
Polar22% (7)N Q S T
Special9% (3)G P

32 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile0 · 0%

L Leu4 · 13%

M Met1 · 3%

V Val2 · 6%

F Phe2 · 6%

W Trp3 · 9%

Y Tyr0 · 0%

H His0 · 0%

K Lys5 · 16%

R Arg3 · 9%

D Asp1 · 3%

E Glu1 · 3%

N Asn1 · 3%

Q Gln3 · 9%

S Ser2 · 6%

T Thr1 · 3%

C Cys0 · 0%

G Gly1 · 3%

P Pro2 · 6%

3D structure

PredictedAlphaFold DB · P04637

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

PNC-27 has 32 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16201774(opens in a new tab)

C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)N[C@@H](CC7=CNC8=CC=CC=C87)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]9CCCN9C(=O)[C@@H]1CCCN1)O

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.324
μH, best 11-residue window: 0.713
Arrow direction: 298°
Residues: 32 · 2 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	P	0°	0.12
2	P	100°	0.12
3	L	200°	1.06
4	S	300°	-0.18
5	Q	40°	-0.85
6	E	140°	-0.74
7	T	240°	-0.05
8	F	340°	1.19
9	S	80°	-0.18
10	D	180°	-0.90
11	L	280°	1.06
12	W	20°	0.81
13	K	120°	-1.50
14	L	220°	1.06
15	L	320°	1.06
16	K	60°	-1.50
17	K	160°	-1.50
18	W	260°	0.81
19	K	0°	-1.50
20	M	100°	0.64
21	R	200°	-2.53
22	R	300°	-2.53
23	N	40°	-0.78
24	Q	140°	-0.85
25	F	240°	1.19
26	W	340°	0.81
27	V	80°	1.08
28	K	180°	-1.50
29	V	280°	1.08
30	Q	20°	-0.85
31	R	120°	-2.53
32	G	220°	0.48

Results by area

PNC-27 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

20 of 24 studies have results (83%), published 2004 to 2025. Top row: every study. Bottom row: studies with results about PNC-27, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies24 in all, 2004 to 2025

Studies with results20 in all, 2004 to 2025

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

PNC-27 studies on cancer

13 results · people 0 · animals 3 · lab 10

Top 3 of 13 results

In mice with human or mouse leukemia, PNC‑27 killed bulk leukemia blasts in primary transplant experiments.Leukemia, 2020
In animals, PNC‑27 caused tumor nodule necrosis.Anticancer research, 2021
In mice with human or mouse leukemia, PNC‑27 killed leukemia stem cells in secondary transplant experiments.Leukemia, 2020

PNC-27 studies on side effects

6 results · people 0 · animals 2 · lab 4

Top 3 of 6 results

In mice, PNC‑27 spared normal blood stem cell activity in primary and secondary bone marrow transplant experiments.Leukemia, 2020
In animals, PNC‑27 did not cause normal tissue necrosis.Anticancer research, 2021
In cells from a normal breast epithelial line, cells remained alive during PNC‑27 exposure, unlike cancer cells.Cancer chemotherapy and pharmacology, 2010

PNC-27 studies on receptors and cell signals

21 results · people 0 · animals 0 · lab 21

Top 3 of 21 results

In cells, PNC‑27 bound HDM-2 in cell membranes.Proceedings of the National Academy of Sciences of the United States of America, 2010
In cells from breast cancer, intact labeled PNC‑27 accumulated in membrane spots as cells broke apart.Cancer chemotherapy and pharmacology, 2010
In cells, PNC‑27 bound to membrane HDM2 in leukemia blasts.Leukemia, 2020

PNC-27 studies on cells, genes and aging

1 result · people 0 · animals 0 · lab 1

1 result

In cells, mitochondria failed to retain the mitochondrial dye after PNC‑27 treatment.Annals of clinical and laboratory science, 2024

Trials and papers

PNC-27 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

24 studies match. Retracted studies are left out.

Showing 24 of 24 studiesquery qry_901082d55685852cee56e55b

Studies with results

20 studies

In vitro (cells) · 2010

5 results

Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

Yang et al. 2010The Journal of biological chemistrycited by 32

PMID 20484051PMC2919130DOI 10.1074/jbc.m109.089417PUB-20484051

CC BY1 result where PNC-27 was given (plus 4 on tools or combinations, listed separately)

Download PDF See results (5)

Not a test of PNC-27 alone · 2004

3 results

NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.

Rosal et al. 2004Biochemistrycited by 28

PMID 14967026DOI 10.1021/bi035718gPUB-14967026

Full text at the publisher3 results where PNC-27 was a tool, carrier or part of a combination

Publisher page See results (3)

Not a test of PNC-27 alone · 2014

2 results

Design and implementation of a high yield production system for recombinant expression of peptides.

Rodríguez et al. 2014Microbial cell factoriescited by 28

PMID 24885242PMC4022411DOI 10.1186/1475-2859-13-65PUB-24885242

CC BY2 results where PNC-27 was a tool, carrier or part of a combination

Download PDF See results (2)

In vitro (cells) · 2010

3 results

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

Sarafraz-Yazdi et al. 2010Proceedings of the National Academy of Sciences of the United States of Americacited by 23

PMID 20080680PMC2836618DOI 10.1073/pnas.0909364107PUB-20080680

Rights unknown1 result where PNC-27 was given (plus 2 on tools or combinations, listed separately)

Source link See results (3)

Not a test of PNC-27 alone · 2017

6 results

PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.

Darban et al. 2017Nanomedicine (London, England)cited by 21

PMID 28565974DOI 10.2217/nnm-2017-0069PUB-28565974

Full text at the publisher6 results where PNC-27 was a tool, carrier or part of a combination

Publisher page See results (6)

Not a test of PNC-27 alone · 2016

1 result

P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.

Mokhtarzadeh et al. 2016Expert opinion on drug deliverycited by 19

PMID 26654047DOI 10.1517/17425247.2016.1126245PUB-26654047

Full text at the publisher1 result where PNC-27 was a tool, carrier or part of a combination

Publisher page See results (1)

In vitro (cells) · 2010

3 results

The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.

Sookraj et al. 2010Cancer chemotherapy and pharmacologycited by 15

PMID 20182728DOI 10.1007/s00280-009-1166-7PUB-20182728

Full text at the publisher3 results where PNC-27 was given

Publisher page See results (3)

In vitro (cells) · murine · 2014

3 results

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Davitt et al. 2014Annals of clinical and laboratory sciencecited by 14

PMID 25117093PUB-25117093

Full text at the publisher3 results where PNC-27 was given

Publisher page See results (3)

Animal study (in vivo) · mouse · 2020

9 results

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

Wang et al. 2020Leukemiacited by 14

PMID 31337857PMC7951797DOI 10.1038/s41375-019-0522-9PUB-31337857

Rights unknown9 results where PNC-27 was given

Source link See results (9)

In vitro (cells) · 2022

3 results

PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

Sarafraz-Yazdi et al. 2022Biomedicinescited by 8

PMID 35625682PMC9138867DOI 10.3390/biomedicines10050945PUB-35625682

CC BY2 results where PNC-27 was given (plus 1 on tools or combinations, listed separately)

Download PDF See results (3)

Not a test of PNC-27 alone · 2023

2 results

The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.

Soriano-Correa et al. 2023Journal of molecular graphics & modellingcited by 7

PMID 37086514DOI 10.1016/j.jmgm.2023.108472PUB-37086514

Full text at the publisher2 results where PNC-27 was a tool, carrier or part of a combination

Publisher page See results (2)

Not a test of PNC-27 alone · 2015

2 results

Production of cell-penetrating peptides in Escherichia coli using an intein-mediated system.

Rodríguez et al. 2015Applied biochemistry and biotechnologycited by 6

PMID 25586490DOI 10.1007/s12010-015-1484-7PUB-25586490

Full text at the publisher2 results where PNC-27 was a tool, carrier or part of a combination

Publisher page See results (2)

Not a test of PNC-27 alone · 2023

1 result

Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.

Miller et al. 2023Biomedicinescited by 6

PMID 37760956PMC10526402DOI 10.3390/biomedicines11092515PUB-37760956

CC BY1 result where PNC-27 was a tool, carrier or part of a combination

Download PDF See results (1)

In vitro (cells) · 2015

3 results

Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.

Sarafraz-Yazdi et al. 2015Annals of clinical and laboratory sciencecited by 4

PMID 26663795PUB-26663795

Full text at the publisher3 results where PNC-27 was given

Publisher page See results (3)

Animal study (in vivo) · 2021

7 results

Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.

Thadi et al. 2021Anticancer researchcited by 4

PMID 33419797DOI 10.21873/anticanres.14749PUB-33419797

Full text at the publisher7 results where PNC-27 was given

Publisher page See results (7)

Not a test of PNC-27 alone · 2022

7 results

Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study.

Rahmani et al. 2022Iranian journal of basic medical sciencescited by 2

PMID 36311203PMC9588323DOI 10.22038/ijbms.2022.65590.14430PUB-36311203

CC BY7 results where PNC-27 was a tool, carrier or part of a combination

Download PDF See results (7)

In vitro (cells) · 2020

3 results

Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.

Thadi et al. 2020Anticancer researchcited by 1

PMID 32878773DOI 10.21873/anticanres.14488PUB-32878773

Full text at the publisher3 results where PNC-27 was given

Publisher page See results (3)

In vitro (cells) · 2020

4 results

Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.

Thadi et al. 2020Annals of clinical and laboratory sciencecited by 1

PMID 33067207PUB-33067207

Full text at the publisher4 results where PNC-27 was given

Publisher page See results (4)

In vitro (cells) · 2024

4 results

Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.

Krzesaj et al. 2024Annals of clinical and laboratory sciencecited by 1

PMID 38802154PUB-38802154

Full text at the publisher3 results where PNC-27 was given (plus 1 on tools or combinations, listed separately)

Publisher page See results (4)

In vitro (cells) · 2025

4 results

HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.

Krzesaj et al. 2025Annals of clinical and laboratory science

PMID 40750238PUB-40750238

Full text at the publisher2 results where PNC-27 was given (plus 2 on tools or combinations, listed separately)

Publisher page See results (4)

More studies

4 studies

PubMed tag: none · 2008

The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.

Bowne et al. 2008Annals of surgical oncologycited by 14

PMID 18931881DOI 10.1245/s10434-008-0147-0PUB-18931881

Full text at the publisher

Publisher page

PubMed tag: Review · 2011

Anti-cancer peptides from ras-p21 and p53 proteins.

Pincus et al. 2011Current pharmaceutical designcited by 4

PMID 21728981DOI 10.2174/138161211797416075PUB-21728981

Full text at the publisher

Publisher page

PubMed tag: none · 2007

Electronic structure and physicochemical properties characterization of the amino acids 12-26 of TP53: a theoretical study.

Barrientos-Salcedo et al. 2007The journal of physical chemistry. Acited by 3

PMID 17472350DOI 10.1021/jp067841yPUB-17472350

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2024

Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.

Pincus et al. 2024Biomedicines

PMID 38927351PMC11201261DOI 10.3390/biomedicines12061144PUB-38927351

CC BY

Download PDF

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

PNC-27 studies: 20 papers with results

Page 1 of 1

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
Wang H · Leukemia · 2020
Animal study (in vivo) · mouse · 9 results
Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
Thadi A · Anticancer research · 2021
Animal study (in vivo) · 7 results
Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.
Yang H · The Journal of biological chemistry · 2010
In vitro (cells) · 5 results
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Sarafraz-Yazdi E · Proceedings of the National Academy of Sciences of the United States of America · 2010
In vitro (cells) · 3 results
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
Sookraj KA · Cancer chemotherapy and pharmacology · 2010
In vitro (cells) · 3 results
The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
Davitt K · Annals of clinical and laboratory science · 2014
In vitro (cells) · murine · 3 results
PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Sarafraz-Yazdi E · Biomedicines · 2022
In vitro (cells) · 3 results
Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
Sarafraz-Yazdi E · Annals of clinical and laboratory science · 2015
In vitro (cells) · 3 results
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
Krzesaj P · Annals of clinical and laboratory science · 2024
In vitro (cells) · 4 results
Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
Thadi A · Anticancer research · 2020
In vitro (cells) · 3 results
Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Thadi A · Annals of clinical and laboratory science · 2020
In vitro (cells) · 4 results
HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.
Krzesaj PK · Annals of clinical and laboratory science · 2025
In vitro (cells) · 4 results
Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study.
Rahmani R · Iranian journal of basic medical sciences · 2022
Not a test of PNC-27 alone · 7 results
PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.
Darban SA · Nanomedicine (London, England) · 2017
Not a test of PNC-27 alone · 6 results
NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
Rosal R · Biochemistry · 2004
Not a test of PNC-27 alone · 3 results
Design and implementation of a high yield production system for recombinant expression of peptides.
Rodríguez V · Microbial cell factories · 2014
Not a test of PNC-27 alone · 2 results
The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.
Soriano-Correa C · Journal of molecular graphics & modelling · 2023
Not a test of PNC-27 alone · 2 results
Production of cell-penetrating peptides in Escherichia coli using an intein-mediated system.
Rodríguez V · Applied biochemistry and biotechnology · 2015
Not a test of PNC-27 alone · 2 results
P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.
Mokhtarzadeh A · Expert opinion on drug delivery · 2016
Not a test of PNC-27 alone · 1 result
Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.
Miller AI · Biomedicines · 2023
Not a test of PNC-27 alone · 1 result

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The openFDA active ingredient search returned no matches. This confirms no matching entry in this database, not worldwide absence of approval.	21 Oct 2026	api.fda.gov (opens in a new tab)
EU	EMA	No authorised exact product match was found in the EMA central medicine catalogue. National authorisations are outside this check.	21 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S0) PNC-27 is not named.	2026 List	wada-ama.org (opens in a new tab)

Safety outcomes

6 safety results for PNC-27.

No safety results from studies in people

The safety results below come from animal or lab studies. They do not show what happens in people.

Animal evidence· 2

In wild-type mice, PNC‑27 spared normal hematopoietic stem cell activity in primary and secondary bone marrow transplant experiments.
Animal study (in vivo)mouse
In an in vivo colon cancer model, PNC‑27 did not cause normal tissue necrosis.
Animal study (in vivo)

Lab evidence· 4

In untransformed MCF-10-2A cells, viability persisted during PNC‑27 exposure, unlike the cancer cells.
In vitro (cells)human
In murine lymphocyte control cells, PNC‑27 had no effect on viability.
In vitro (cells)murine
In non-transformed HUVEC, no PNC‑27 cytotoxicity was observed.
In vitro (cells)human
In normal human PCS-480 cervical cells, PNC‑27 was not cytotoxic.
In vitro (cells)human

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000087
Peptide version: 4
Peptide hash: 3a0ad1077505a81c…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256762
22 Oct 2026UpdatedData version 254564
21 Oct 2026UpdatedData version 226603
21 Oct 2026CreatedData version 213654

For developers

curl -s https://pepbank.io/v1/briefs/pnc-27

Evidence summary for PNC-27: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Receptor activity and mechanismCancer	No results	No results	Lab: 21 results from 9 studies: 5 increase, 1 mixed, 15 not reported. Strongest design: In vitro (cells)	No results	21
Tumor growthCancer	No results	Animal: 3 results from 2 studies: 3 increase. Strongest design: Animal study (in vivo)	Lab: 10 results from 8 studies: 8 increase, 2 decrease. Strongest design: In vitro (cells)	No results	13
Adverse eventsCancer	No results	Animal: 2 results from 2 studies: 2 not reported. Strongest design: Animal study (in vivo)	Lab: 4 results from 4 studies: 3 no significant change, 1 not reported. Strongest design: In vitro (cells)	No results	6
Mitochondrial functionCancer	No results	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells)	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Receptor activity and mechanismCancer	No results	No results	Lab: 21 results from 9 studies: 5 increase, 1 mixed, 15 not reported. Strongest design: In vitro (cells)	No results	21
Tumor growthCancer	No results	Animal: 3 results from 2 studies: 3 increase. Strongest design: Animal study (in vivo)	Lab: 10 results from 8 studies: 8 increase, 2 decrease. Strongest design: In vitro (cells)	No results	13
Adverse eventsCancer	No results	Animal: 2 results from 2 studies: 2 not reported. Strongest design: Animal study (in vivo)	Lab: 4 results from 4 studies: 3 no significant change, 1 not reported. Strongest design: In vitro (cells)	No results	6
Mitochondrial functionCancer	No results	No results	Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells)	No results	1

PNC-27 studies and research data

PNC-27 identity

Targets

Sequence and structure

Sequence

Parent: Cellular tumor antigen p53

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

PNC-27 results by year and outcome

What the studies measured

PNC-27 studies on cancer

PNC-27 studies on side effects

PNC-27 studies on receptors and cell signals

PNC-27 studies on cells, genes and aging

PNC-27 trials

Papers

Studies with results

Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.

Design and implementation of a high yield production system for recombinant expression of peptides.

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.

P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.

The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.

Production of cell-penetrating peptides in Escherichia coli using an intein-mediated system.

Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.

Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.

Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.

Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study.

Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.

Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.

Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.

HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.

More studies

The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells.

Anti-cancer peptides from ras-p21 and p53 proteins.

Electronic structure and physicochemical properties characterization of the amino acids 12-26 of TP53: a theoretical study.

Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.

Newer studies

PNC-27 studies: 20 papers with results

Regulatory and safety

Animal evidence· 2

Lab evidence· 4

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

PNC-27 results by year and outcome

PNC-27 studies on cancer

PNC-27 studies on side effects

PNC-27 studies on receptors and cell signals

PNC-27 studies on cells, genes and aging

PNC-27 trials

Papers

Studies with results

Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides.

NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.

Design and implementation of a high yield production system for recombinant expression of peptides.

Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.

PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.

P53-Derived peptides conjugation to PEI: an approach to producing versatile and highly efficient targeted gene delivery carriers into cancer cells.

The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.

The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies.

Production of cell-penetrating peptides in Escherichia coli using an intein-mediated system.

Ketone Bodies Induce Unique Inhibition of Tumor Cell Proliferation and Enhance the Efficacy of Anti-Cancer Agents.

Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.

Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.